Chikungunya Vaccine Resource Center

Chikungunya virus (CHIKV) is transmitted to humans via the bite of an infected Aedes aegypti or Aedes albopictus mosquito. Risk of chikungunya is greatest to travelers in areas experiencing ongoing chikungunya outbreaks.

Approximately 3%–28% of people infected with CHIKV will remain asymptomatic. For people who develop symptomatic illness, disease is most often characterized by sudden onset of high fever and joint pains. Other symptoms may include conjunctivitis, headache, myalgia, nausea, vomiting, or a rash. Patient management focuses on supportive care.

Chikungunya may be prevented by using personal protective measures to prevent mosquito bites. Chikungunya may also be prevented by vaccination. In 2023, the U.S. Food and Drug Administration licensed a vaccine for chikungunya called IXCHIQ. IXCHIQ contains a live attenuated virus. It is administered intramuscularly, as a single lifetime dose, to eligible adults.

Chikungunya vaccine is recommended for persons ages 18 years and older who are traveling to a country or territory where there is an active chikungunya outbreak. Outbreaks are defined by public health authorities and posted on the CDC website Areas at Risk for Chikungunya.

In addition, certain laboratory workers with potential for exposure to CHIKV are eligible to receive the vaccine.

Chikungunya vaccination may be considered for certain individuals traveling to a country or territory without an outbreak but with evidence of CHIKV transmission among humans within the last 5 years. These individuals include:

• People aged 65 years or older, particularly those with underlying medical conditions, likely to have at least moderate exposure to mosquitoes.
• People aged 18 years or older who are staying for a cumulative period of 6 months or more.  

Resource Center

You will find below all of the resources you will need about the chikungunya vaccine. More will be added as they are published or released.